BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PF-06651600 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PF-06651600\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07029711-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07029711)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study to Learn About Medicine 
 Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alo
 pecia Areata\nEstimated primary completion: 2 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07029711
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228390-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07228390)
DESCRIPTION:PF-06651600\, phase 2.\nStudy: A 16-Week Study to Learn About t
 he Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful 
 Red Skin Lumps\, Known by the Medical Term\, Hidradenitis Suppurativa\, or
  HS.\nEstimated primary completion: 8 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07228390
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219615-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07219615)
DESCRIPTION:PF-06651600\, phase 2.\nStudy: A Study to Learn About Ritleciti
 nib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults
 .\nEstimated primary completion: 25 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07219615
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163326-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06163326)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 52-Week Study to Le
 arn About the Safety and Effects of Ritlecitinib in Participants With Nons
 egmental Vitiligo\nEstimated primary completion: 31 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06163326
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072183-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06072183)
DESCRIPTION:PF-06651600\, phase 3\, Vitiligo.\nStudy: A 104-Week Study of R
 itlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and
  Stable) Tranquillo 2\nEstimated primary completion: 30 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06072183
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06373458-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:PF-06651600: Phase 2 readout est. (NCT06373458)
DESCRIPTION:PF-06651600\, phase 2.\nStudy: Ritlecitinib in Patients With Ke
 loids or Those Undergoing Keloidectomy\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-06651600#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0637
 3458
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06873945-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20280319
DTEND;VALUE=DATE:20280320
SUMMARY:PF-06651600: Phase 3 readout est. (NCT06873945)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study of 2 Doses of Ritlecitin
 ib in People 12 Years of Age and Older With Alopecia Areata\nEstimated pri
 mary completion: 19 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06873945
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733765-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07733765)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Study in Young People and Adul
 ts to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair L
 oss\, Known by the Medical Term as Moderate Alopecia Areata\nEstimated pri
 mary completion: 26 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pf-06651600#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07733765
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152626-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:PF-06651600: Phase 2 readout est. (NCT07152626)
DESCRIPTION:PF-06651600\, phase 2\, Vitiligo.\nStudy: Combination Approach 
 With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vi
 tiligo\nEstimated primary completion: 1 January 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07152626
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029828-5938@assetmemo.bio
DTSTAMP:20261121T004111Z
DTSTART;VALUE=DATE:20300626
DTEND;VALUE=DATE:20300627
SUMMARY:PF-06651600: Phase 3 readout est. (NCT07029828)
DESCRIPTION:PF-06651600\, phase 3.\nStudy: A Long-Term Study to Learn About
  The Study Medicine Called Ritlecitinib in Children With Severe Alopecia A
 reata.\nEstimated primary completion: 26 June 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pf-06651600#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07029828
URL:https://assetmemo.bio/drug/pf-06651600#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
